Medtronic likely to continue with spin off plan as buyer interest cools - report
JHVEPhoto/iStock Editorial via Getty Images
Medtronic Plc (NYSE:MDT) appears likely to continue with a plan off its patient-monitoring and lung-treatment businesses after potential sale interest cools. 
Talks with private equity firm Carlyle Group (CG) have slowed and the strategic bidder's interest has waned, according to a Bloomberg report on Monday, which cited people familiar with the situation. Medtronic (MDT) was seeking to sell the businesses for about $10 billion. 
The update comes after Bloomberg reported in December that Siemens Healthineers AG (OTCPK:SEMHF) and GE Healthcare (GEHC) were among the companies in the race to acquire two businesses that Medtronic (MDT) was set to spin off.
In October, Dublin-based medical device maker Medtronic (MDT) announced it would separate the company's combined patient monitoring and respiratory interventions businesses over the next 12 â 18 months.
In the same article on Monday, Bloomberg also reported that Dentsply Sirona's (NASDAQ:XRAY) possible $1 billion sale of its medical product unit, Wellspect HealthCare, was said to be stalling after buyout firms' bid didn't meet expectations. Bloomberg reported in February that Dentsply was exploring options for bladder and bowel-control product unit Wellspect. 
More on Medtronic

Medtronic: Solid Q4 Earnings, Don't Fret About Guidance
Why Medtronic Could Have 25% Upside From Today's Levels
Why 2023 is turning into the year of the healthcare spinoff